Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
Intravitreal complement inhibitor treatment for GA viewed favorably by patients | Ophthalmology Times
(Image Credit: AdobeStock) A new British study reported that treatment with intravitreal complement inhibitors (IVCIs) for geographic atrophy (GA) was viewed favorably by patients if the treatment was thought to impart visual benefits,1 according to first author Christiana Dinah, BSc,…
Vizz officially launches in the United States | Ophthalmology Times
(Image Credit: AdobeStock) Following a US Food and Drug Administration approval back in July 2025, LENZ Therapeutics has announced that VIZZ (aceclidine ophthalmic solution) 1.44% is now commercially available.1 The first and only FDA-approved aceclidine-based eye drop is for the…
David Lally discusses the ARCHER trial and the optimistic outcomes fueling future research | Ophthalmology Times
Note: Video captions are generated with the assistance of AI and may contain errors. David Lally, MD, presented at the 2025 Retina Society meeting, discussing the ARCHER study (NCT04656561) of ANX007 for the treatment of age-related macular degeneration (AMD) and…
Q&A: Mario Romano discusses temperature during vitrectomy | Ophthalmology Times
Photo of Mario Romano at EURETINA 2025 Mario Romano, MD, PhD, a researcher from Humanitas University in Italy, discusses work on temperature control during vitrectomy. His research, supported by the Italian Ministry of Research, reveals significant temperature drops during eye…
Q&A: Nadia Waheed on the role of OCT in the future of ophthalmology | Ophthalmology Times
Photo of Nadia Waheed at the 2025 EURETINA meeting held in Paris, France Ultra High Resolution OCT is revolutionizing retinal imaging, offering unprecedented insights into eye diseases. Nadia Waheed, MD, MPH, from Tufts University School of Medicine discusses how this…
Positive pediatric data emerge from the OPGx-LCA5 phase 1/2 trial of Leber congenital amaurosis type 5 | Ophthalmology Times
Image credit: AdobeStock/arturkowynia Opus Genetics today announced the positive 3-month pediatric data from its Phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5, an investigational gene therapy for Leber congenital amaurosis type 5 (LCA5), an ultra-rare form…
Q&A: Patricio Schlottmann discusses results of AVONELLE-X faricimab extension trial | Ophthalmology Times
Photo of Patricio Schlottmann at the 2025 EURETINA meeting in Paris, France Patricio Schlottmann, MD, a retina specialist from Buenos Aires, Argentina, discusses the AVONELLE-X extension study of faricimab, a treatment for wet age-related macular degeneration (AMD). The study, spanning…
Researchers assess atropine and cyclopentolate for detecting premyopia in young children | Ophthalmology Times
(Image Credit: AdobeStock) A comparison of 2 cycloplegic agents, atropine and cyclopentolate, in preschool children for cycloplegia found that atropine was associated with less myopic refraction compared with cyclopentolate and may potentially avoid the overestimation of premyopia prevalence,1 reported first…
Kala Bio’s CHASE trial misses primary endpoint, KPI-012 development discontinued | Ophthalmology Times
(Image Credit: AdobeStock) Kala Bio announced that CHASE (NCT05727878), its phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect (PCED), did not meet its primary endpoint. Additionally, the company noted that the trial failed to show statistical significance…
Q&A: Marion Munk discusses the phase 2a BETTER study | Ophthalmology Times
Photo of Marion Munk at EURETINA 2025 In her conversation with the Eye Care Network, Marion Munk, MD, PhD, details a promising phase 2a clinical study of ISTH0036, an oligonucleotide antisense drug targeting TGF-β2. Developed to address fibrosis in neovascular…